Skip to main content

Abeona Therapeutics Inc.

ABEO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000318306

In the last 90 days, Abeona Therapeutics Inc. insiders filed 0 open-market purchases and 7 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $275.1M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $981.0K in total
7
13F holdersQ2 2026, +19 vs. previous quarter
126
13F valueReported value at the end of Q2 2026
$275.1M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding ABEO, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ABEO at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Abeona Therapeutics Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 1, 2026 (view filing)5:48 PM ETSep 1Same dayAlvino MarkDirectorSSale−15.0K$5.86−$88.0K−19.5%62.1K after
Jul 22, 2026 (view filing)4:30 PM ETJul 211 dayVazzano Joseph WalterChief Financial OfficerSSale−1.48K$6.53−$9.65K−0.3%492.1K after
Jul 9, 2026 (view filing)7:24 PM ETJul 9Same dayVazzano Joseph WalterChief Financial OfficerSSale−24.9K$6.96−$173.3K−4.8%493.6K after
Jul 9, 2026 (view filing)7:22 PM ETJul 9Same daySeshadri VishwasChief Executive OfficerSSale−68.0K$6.96−$473.3K−4.9%1.31M after
Jul 9, 2026 (view filing)7:20 PM ETJul 9Same dayO'Malley Brendan M.SVP, Chief Legal OfficerSSale−12.1K$6.96−$83.9K−2.7%428.0K after
Jul 9, 2026 (view filing)7:17 PM ETJul 9Same dayVasanthavada MadhavChief Commercial OfficerSSale−12.6K$6.96−$87.8K−4.2%290.6K after
Jul 2, 2026 (view filing)4:30 PM ETJun 302 daysAlland LeilaDirectorSSale−11.0K$5.92−$65.1K−6.3%162.6K after
Jun 15, 2026 (view filing)Jun 15Same daySilverstein Christine BerniDirectorSSale−18.2K$5.71−$103.7K−13.2%119.6K after
Jun 9, 2026 (view filing)Jun 8-91 dayVazzano Joseph WalterChief Financial OfficerSSale−49.3K$5.37−$265.1K−8.7%518.4K after3 lots10b5-1
Jun 9, 2026 (view filing)Jun 8-91 dayVasanthavada MadhavChief Commercial OfficerSSale−9.62K$5.36−$51.5K−3.1%303.5K after2 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in Abeona Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 126 holders
Institutions holding ABEO in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Nantahala Capital Management, LLC10,272,980$63.5M1.92%+5,259,928+104.9%Added
BlackRock, Inc.3,352,474$20.7M0.00%+156,944+4.9%Added
Cable Car Capital LLC3,007,329$18.6M0.40%00.0%Unchanged
AIGH Capital Management LLC2,987,000$18.5M1.67%−113,000−3.6%Reduced
Vanguard Capital Management LLC2,211,433$13.7M0.00%+46,582+2.2%Added
Resources Investment Advisors, LLC.1,653,024$10.2M0.09%+1,653,024New
AWM Investment Company, Inc.1,486,130$9.18M0.80%+683,000+85.0%Added
Geode Capital Management, LLC1,261,090$7.80M0.00%+51,293+4.2%Added
Kennedy Capital Management, Inc.1,240,071$7.66M0.14%−23,440−1.9%Reduced
Goldman Sachs Group Inc1,224,806$7.57M0.00%+94,187+8.3%Added